NCT06679985 2026-02-05
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Recruiting
Clinical Trials
17 trialsNCT04374877 2025-11-10
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT06882876 2025-09-19
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
Xiangya Hospital of Central South University
Phase 1 Enrolling by invitation
NCT03474640 2024-11-22
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Completed
NCT06201065 2024-01-11
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT03867370 2023-11-29
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Terminated
NCT04135690 2023-08-15
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
Phase 2 Unknown
NCT04044313 2023-06-12
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
Sun Yat-sen University
Phase 2 Completed
NCT04368078 2023-03-29
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03864211 2022-09-29
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT05493332 2022-08-18
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05240404 2022-02-15
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05056337 2021-09-24
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
Shanghai Zhongshan Hospital
Phase 3 Unknown
NCT04926532 2021-06-15
Toripalimab
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT04170179 2021-02-23
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
Sun Yat-sen University
Phase 2 Unknown
NCT03919383 2019-06-03
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn